Paper Details

  1. Home
  2. Paper Details

Avatrombopag for the treatment of immune thrombocytopenia.

Author: Długosz-DaneckaMonika, JurczakWojciech, ZdziarskaJoanna

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Avatrombopag, a new drug used to treat thrombocytopenia, has a good safety profile and is effective in increasing platelet counts.
Paper Details　
Original Abstract of the Article :
Label="INTRODUCTION">Thrombopoietin-receptor agonists (TPO-RAs) are the only American Society of Hematology (ASH) guideline-advocated, second-line treatment for immune thrombocytopenia (ITP) that have been validated by randomized, controlled trials with a placebo comparator. Avatrombopag is a new ca...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/1744666X.2019.1587294

データ提供：米国国立医学図書館（NLM）

Avatrombopag: A New Oasis in the Desert of Immune Thrombocytopenia (ITP)

Immune thrombocytopenia (ITP) is a condition characterized by a low platelet count, often leading to excessive bleeding. This study examines the potential of avatrombopag, a new thrombopoietin-receptor agonist (TPO-RA), as a treatment for ITP.

The study highlights avatrombopag's ability to significantly increase platelet counts, reducing the need for platelet transfusions and rescue medications. The study notes that avatrombopag's oral delivery, convenient dosing schedule, and good tolerability make it a promising candidate for second-line treatment of ITP.

A Camel's Oasis for Thrombocytopenia Management

The study's findings suggest that avatrombopag could be a valuable treatment option for ITP, offering a potential solution for patients who are not adequately responding to other therapies.

A Camel's Compass for ITP Treatment

This research underscores the importance of individualized treatment approaches for ITP, tailoring therapy to the specific needs of each patient. While avatrombopag shows promise, it is crucial to consult with a healthcare professional to determine the most appropriate treatment plan.

Dr. Camel's Conclusion

This study offers a glimpse of a new oasis in the desert of ITP treatment, exploring the potential of avatrombopag as a safe and effective option. The study's findings hold promise for improving the lives of patients with ITP, but further research is needed to fully assess its long-term efficacy and safety.

Date :
  1. Date Completed 2020-05-25
  2. Date Revised 2020-05-25
Further Info :

Pubmed ID

30799645

DOI: Digital Object Identifier

10.1080/1744666X.2019.1587294

Related Literature

Article Analysis
・Effects of avatrombopag
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.